Using Gene Expression Profiling to Personalize Skin Cancer Management.

Area of Science:

• Oncology
• Genomics
• Dermatology

Background:

• Traditional cancer staging has limitations in identifying high-risk patients for certain skin cancers.
• Objective metrics are needed to complement clinicopathological staging for improved patient management.
• Gene expression profiling (GEP) offers a valuable tool for risk stratification in cutaneous malignancies.

Purpose of the Study:

• To evaluate the utility of gene expression profiling (GEP) tests in improving risk stratification for melanoma and cutaneous squamous cell carcinoma (cSCC).
• To demonstrate how GEP can guide personalized clinical management and surveillance decisions for skin cancer patients.
• To highlight the integration of GEP with clinicopathological features for enhanced prognostic accuracy.

Main Methods:

• Utilized the 31-gene expression profile (31-GEP) test for melanoma, integrating results with clinicopathological features to assess risk of recurrence (ROR) and sentinel lymph node biopsy (SLNB) likelihood.
• Employed the 40-gene expression profile (40-GEP) test for cSCC patients with risk factors to identify those at high risk of metastasis.
• Assessed the clinical applicability and integration of these GEP tests into standard practice.

Main Results:

• The i31-GEP test provides personalized prognostic information for melanoma patients, aiding in risk-appropriate management and surveillance.
• The 40-GEP test effectively stratifies risk in cSCC patients, identifying individuals with a higher likelihood of developing metastasis.
• GEP tests offer objective metrics that supplement traditional staging, particularly for patients lacking conventional risk markers.

Conclusions:

• Gene expression profiling tests significantly enhance the risk-stratification capabilities for melanoma and cSCC.
• These GEP-based tools facilitate personalized treatment and surveillance strategies, leading to improved patient outcomes.
• The integration of GEP into clinical practice represents a significant advancement in managing high-risk skin cancers.